Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial design

  • Luca Bertolaccini1,2
  • Monica Casiraghi1,2
  • Antonio Mazzella2
  • Giorgio Lo Iacono2
  • Lorenzo Spaggiari1,2
  1. 1Department of Oncology and Hemato-Oncology, University of Milan
  2. 2Department of Thoracic Surgery, European Institute of Oncology IRCCS
Open at sourcePDFDOICite

Related

  1. Quantitative systems pharmacology modeling of class I–III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design
    Jingjing Hu, Qi Rao, Zichun Li +5
    iSciencePeer-reviewedCC BY 4.0Full textOncologyPharmacology & toxicologyCell PressCrossrefEurope PMC
  2. Entrectinib-associated perimyocarditis in ROS1-positive NSCLC: a diagnostic and therapeutic dilemma — a case report
    Malwina Sołtysiak, Paweł Śliwiński
    Frontiers in MedicinePeer-reviewedCC BYFull textGeneral medicineDOAJ
  3. A structural dose-response relationship between lymph node yield and survival after anatomical segmentectomy for early-stage NSCLC: a SEER-based retrospective cohort study
    Ye Tian, Edoardo Zanfrini, Etienne Abdelnour-Berchtold +3
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Feasibility Is Not Benefit: Resectable, Irradiable, or Biologically Selected? A Critical Review of the Unresolved Local-Platform Question in Stage III/N2 NSCLC
    Panteleimonas Skarlos, Ioannis Georgakopoulos, Andromachi Kougioumtzopoulou +6
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  5. Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
    Pragya Rai, Yu-Han Kao, Xiaohan Hu +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{bertolaccini2026dilemma,
  title = {{The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial design}},
  author = {Luca Bertolaccini and Monica Casiraghi and Antonio Mazzella and Giorgio Lo Iacono and Lorenzo Spaggiari},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1866606},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1866606/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The N2 dilemma in stage III NSCLC: toward a quantitative framework for trial design
AU  - Luca Bertolaccini
AU  - Monica Casiraghi
AU  - Antonio Mazzella
AU  - Giorgio Lo Iacono
AU  - Lorenzo Spaggiari
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1866606
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1866606/full
SN  - 2234-943X
ER  -